260 related articles for article (PubMed ID: 17512353)
1. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction.
Mocatta TJ; Pilbrow AP; Cameron VA; Senthilmohan R; Frampton CM; Richards AM; Winterbourn CC
J Am Coll Cardiol; 2007 May; 49(20):1993-2000. PubMed ID: 17512353
[TBL] [Abstract][Full Text] [Related]
2. Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction.
Khan SQ; Kelly D; Quinn P; Davies JE; Ng LL
Heart; 2007 Jul; 93(7):826-31. PubMed ID: 17194712
[TBL] [Abstract][Full Text] [Related]
3. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction.
Campbell DJ; Mitchelhill KI; Schlicht SM; Booth RJ
J Card Fail; 2000 Jun; 6(2):130-9. PubMed ID: 10908087
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome.
Cavusoglu E; Ruwende C; Eng C; Chopra V; Yanamadala S; Clark LT; Pinsky DJ; Marmur JD
Am J Cardiol; 2007 May; 99(10):1364-8. PubMed ID: 17493461
[TBL] [Abstract][Full Text] [Related]
5. High plasma N-terminal pro-brain natriuretic peptide level found in diabetic patients after myocardial infarction is associated with an increased risk of in-hospital mortality and cardiogenic shock.
Vergès B; Zeller M; Desgrès J; Dentan G; Laurent Y; Janin-Manificat L; L'Huillier I; Rioufol G; Beer JC; Makki H; Rochette L; Gambert P; Cottin Y
Eur Heart J; 2005 Sep; 26(17):1734-41. PubMed ID: 15831555
[TBL] [Abstract][Full Text] [Related]
6. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction.
Richards AM; Nicholls MG; Espiner EA; Lainchbury JG; Troughton RW; Elliott J; Frampton C; Turner J; Crozier IG; Yandle TG
Circulation; 2003 Jun; 107(22):2786-92. PubMed ID: 12771003
[TBL] [Abstract][Full Text] [Related]
7. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.
Kistorp C; Raymond I; Pedersen F; Gustafsson F; Faber J; Hildebrandt P
JAMA; 2005 Apr; 293(13):1609-16. PubMed ID: 15811980
[TBL] [Abstract][Full Text] [Related]
8. Relation of elevated levels of plasma myeloperoxidase to impaired myocardial microcirculation after reperfusion in patients with acute myocardial infarction.
Yunoki K; Naruko T; Komatsu R; Shirai N; Nakagawa M; Sugioka K; Ikura Y; Kusano KF; Itoh A; Haze K; Yoshiyama M; Becker AE; Ueda M
Am J Cardiol; 2010 Apr; 105(7):922-9. PubMed ID: 20346307
[TBL] [Abstract][Full Text] [Related]
9. High plasma thiocyanate levels are associated with enhanced myeloperoxidase-induced thiol oxidation and long-term survival in subjects following a first myocardial infarction.
Nedoboy PE; Morgan PE; Mocatta TJ; Richards AM; Winterbourn CC; Davies MJ
Free Radic Res; 2014 Oct; 48(10):1256-66. PubMed ID: 25050609
[TBL] [Abstract][Full Text] [Related]
10. Renal and cardiac function for long-term (10 year) risk stratification after myocardial infarction.
Palmer SC; Yandle TG; Frampton CM; Troughton RW; Nicholls MG; Richards AM
Eur Heart J; 2009 Jun; 30(12):1486-94. PubMed ID: 19389787
[TBL] [Abstract][Full Text] [Related]
11. N-terminal probrain natriuretic peptide predicts adverse outcomes in acute-myocardial infarction even with preserved left ventricular ejection fraction.
Puri A; Narain VS; Mehrotra S; Dwivedi SK; Saran RK; Puri VK
Indian Heart J; 2006; 58(2):138-43. PubMed ID: 18989058
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure.
Tang WH; Tong W; Troughton RW; Martin MG; Shrestha K; Borowski A; Jasper S; Hazen SL; Klein AL
J Am Coll Cardiol; 2007 Jun; 49(24):2364-70. PubMed ID: 17572253
[TBL] [Abstract][Full Text] [Related]
13. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.
Kragelund C; Grønning B; Køber L; Hildebrandt P; Steffensen R
N Engl J Med; 2005 Feb; 352(7):666-75. PubMed ID: 15716560
[TBL] [Abstract][Full Text] [Related]
14. N-terminal pro-B-type natriuretic peptide in risk stratification after acute myocardial infarction in patients on long-term beta-adrenergic receptor blocker therapy.
Jonsson G; Abdelnoor M; Landaas S; Muller C; Kjeldsen SE; Os I; Westheim A
Cardiology; 2006; 106(2):102-8. PubMed ID: 16636540
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the N-terminal pro-B-type natriuretic peptide in the elderly with acute myocardial infarction.
Drewniak W; Snopek G; Zarukiewicz M; Borys M; Dabrowski M
Kardiol Pol; 2008 Jul; 66(7):750-5; discussion 756-7. PubMed ID: 18690566
[TBL] [Abstract][Full Text] [Related]
16. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
Khan SQ; Dhillon O; Kelly D; Squire IB; Struck J; Quinn P; Morgenthaler NG; Bergmann A; Davies JE; Ng LL
J Am Coll Cardiol; 2008 May; 51(19):1857-64. PubMed ID: 18466800
[TBL] [Abstract][Full Text] [Related]
17. The usefulness of myeloperoxidase in prediction of in-hospital mortality in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Stankovic S; Asanin M; Majkic-Singh N; Ignjatovic S; Mihailovic M; Nikolajevic I; Mrdovic I; Matic D; Savic L; Marinkovic J; Ostojic M; Vasiljevic Z
Clin Lab; 2012; 58(1-2):125-31. PubMed ID: 22372355
[TBL] [Abstract][Full Text] [Related]
18. Integrating plasma high-sensitivity C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure.
Tang WH; Shrestha K; Troughton RW; Borowski AG; Klein AL
Congest Heart Fail; 2011; 17(3):105-9. PubMed ID: 21609382
[TBL] [Abstract][Full Text] [Related]
19. Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction.
Kaya MG; Yalcin R; Okyay K; Poyraz F; Bayraktar N; Pasaoglu H; Boyaci B; Cengel A
Tex Heart Inst J; 2012; 39(4):500-6. PubMed ID: 22949765
[TBL] [Abstract][Full Text] [Related]
20. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy.
Ezekowitz JA; Armstrong PW; Granger CB; Theroux P; Stebbins A; Kim RJ; Patel MR
Am Heart J; 2010 Aug; 160(2):272-8. PubMed ID: 20691832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
